BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

843 related articles for article (PubMed ID: 17953631)

  • 1. Antioxidants and narrow band-UVB in the treatment of vitiligo: a double-blind placebo controlled trial.
    Dell'Anna ML; Mastrofrancesco A; Sala R; Venturini M; Ottaviani M; Vidolin AP; Leone G; Calzavara PG; Westerhof W; Picardo M
    Clin Exp Dermatol; 2007 Nov; 32(6):631-6. PubMed ID: 17953631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study.
    Middelkamp-Hup MA; Bos JD; Rius-Diaz F; Gonzalez S; Westerhof W
    J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):942-50. PubMed ID: 17659004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen-UV-A therapy vs Narrowband-UV-B therapy.
    Yones SS; Palmer RA; Garibaldinos TM; Hawk JL
    Arch Dermatol; 2007 May; 143(5):578-84. PubMed ID: 17519217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blinded, placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo.
    Bakis-Petsoglou S; Le Guay JL; Wittal R
    Br J Dermatol; 2009 Oct; 161(4):910-7. PubMed ID: 19523170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial.
    Esfandiarpour I; Ekhlasi A; Farajzadeh S; Shamsadini S
    J Dermatolog Treat; 2009; 20(1):14-8. PubMed ID: 18608735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response of vitiligo to narrowband ultraviolet B and oral antioxidants.
    Elgoweini M; Nour El Din N
    J Clin Pharmacol; 2009 Jul; 49(7):852-5. PubMed ID: 19553407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacalcitol and narrow-band phototherapy in patients with vitiligo.
    Leone G; Pacifico A; Iacovelli P; Paro Vidolin A; Picardo M
    Clin Exp Dermatol; 2006 Mar; 31(2):200-5. PubMed ID: 16487090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Narrow-band UVB311 nm vs. broad-band UVB therapy in combination with topical calcipotriol vs. placebo in vitiligo.
    Hartmann A; Lurz C; Hamm H; Bröcker EB; Hofmann UB
    Int J Dermatol; 2005 Sep; 44(9):736-42. PubMed ID: 16135141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between 308-nm monochromatic excimer light and narrowband UVB phototherapy (311-313 nm) in the treatment of vitiligo--a multicentre controlled study.
    Casacci M; Thomas P; Pacifico A; Bonnevalle A; Paro Vidolin A; Leone G
    J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):956-63. PubMed ID: 17659006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of narrow band UVB and topical calcipotriol for the treatment of vitiligo.
    Goktas EO; Aydin F; Senturk N; Canturk MT; Turanli AY
    J Eur Acad Dermatol Venereol; 2006 May; 20(5):553-7. PubMed ID: 16684283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of vitiligo with broadband ultraviolet B and vitamins.
    Don P; Iuga A; Dacko A; Hardick K
    Int J Dermatol; 2006 Jan; 45(1):63-5. PubMed ID: 16426381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Narrow-band UVB phototherapy combined with tacrolimus ointment in vitiligo: a review of 110 patients.
    Fai D; Cassano N; Vena GA
    J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):916-20. PubMed ID: 17659000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical calcipotriene and narrowband ultraviolet B in the treatment of vitiligo.
    Kullavanijaya P; Lim HW
    Photodermatol Photoimmunol Photomed; 2004 Oct; 20(5):248-51. PubMed ID: 15379875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrapatient comparison of 308-nm monochromatic excimer light and localized narrow-band UVB phototherapy in the treatment of vitiligo: a randomized controlled trial.
    Verhaeghe E; Lodewick E; van Geel N; Lambert J
    Dermatology; 2011; 223(4):343-8. PubMed ID: 22269666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open randomized study to compare narrow band UVB, topical pimecrolimus and topical tacrolimus in the treatment of vitiligo.
    Stinco G; Piccirillo F; Forcione M; Valent F; Patrone P
    Eur J Dermatol; 2009; 19(6):588-93. PubMed ID: 19651562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical evaluation of the variants influencing the clinical response of vitiligo: study of 60 cases treated with ultraviolet B narrow-band phototherapy.
    Brazzelli V; Antoninetti M; Palazzini S; Barbagallo T; De Silvestri A; Borroni G
    J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1369-74. PubMed ID: 17958843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study.
    Gambichler T; Othlinghaus N; Tomi NS; Holland-Letz T; Boms S; Skrygan M; Altmeyer P; Kreuter A
    Br J Dermatol; 2009 Mar; 160(3):652-8. PubMed ID: 19120333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index.
    Hamzavi I; Jain H; McLean D; Shapiro J; Zeng H; Lui H
    Arch Dermatol; 2004 Jun; 140(6):677-83. PubMed ID: 15210457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of an antioxidant and mitochondria-stimulating cream formula on the skin of patients with stable common vitiligo].
    Rojas-Urdaneta JE; Poleo-Romero AG
    Invest Clin; 2007 Mar; 48(1):21-31. PubMed ID: 17432541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of vitiligo with narrowband-UVB (TL01) combined with tacrolimus ointment (0.1%) vs. placebo ointment, a randomized right/left double-blind comparative study.
    Nordal EJ; Guleng GE; Rönnevig JR
    J Eur Acad Dermatol Venereol; 2011 Dec; 25(12):1440-3. PubMed ID: 21466589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.